HM 2002

Drug Profile

HM 2002

Alternative Names: HM-2002

Latest Information Update: 20 Dec 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hormos Medical; QuatRx Pharmaceuticals
  • Developer Hormos Medical
  • Class Antineoplastics
  • Mechanism of Action Hydroxysteroid dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 20 Dec 2005 Discontinued - Preclinical for Breast cancer in Finland (unspecified route)
  • 20 Dec 2005 Discontinued - Preclinical for Breast cancer prevention in Finland (unspecified route)
  • 16 Jun 2005 Hormos Medical has been acquired and merged into QuatRx Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top